ReviewInternational immunopharmacology2020
The relationship between TIGIT
Review in International immunopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- MYC promotes the progression of prostate cancer by regulating CD47 to induce an immunosuppressive microenvironment.Cellular and molecular life sciences : CMLS · 2026Article
- Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.Signal transduction and targeted therapy · 2026Review
- TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa.Frontiers in immunology · 2026Article
- Exploring the Common Pathogenic Mechanisms of Psoriasis and Atopic Dermatitis: The Interaction between SGK1 and TIGIT Signaling Pathways.Inflammation · 2025Article
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- TIGIT Regulates T Cell Inflammation in Airway Inflammatory Diseases.Inflammation · 2025Review
- Cell-Based Therapeutic Strategies for Autoimmune Diseases.ImmunoTargets and therapy · 2025Review
- The homeostasis and heterogeneity of regulatory T cells in sepsis.Burns & trauma · 2025Article
- Advance in chimeric antigen receptor T therapy in autoimmune diseases.Frontiers in immunology · 2025Review
- Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.Frontiers in immunology · 2025Review
- High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.Molecular therapy. Methods & clinical development · 2024Article
- TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration.Journal of leukocyte biology · 2024Article
- Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGITScientific reports · 2024Article
- High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.bioRxiv : the preprint server for biology · 2024Article
- Associations between type 1 diabetes and pulmonary tuberculosis: a bidirectional mendelian randomization study.Diabetology & metabolic syndrome · 2024Article
- Astragalus Polysaccharide Alleviates Ulcerative Colitis by Regulating the Balance of mTh17/mTreg Cells through TIGIT/CD155 Signaling.Molecules (Basel, Switzerland) · 2024Article
- Single-cell RNA sequencing elucidates cellular plasticity in esophageal small cell carcinoma following chemotherapy treatment.Frontiers in genetics · 2024Article
- Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective.Frontiers in immunology · 2024Review
- Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review.Immunity, inflammation and disease · 2023Review
- A2Ar-dependent PD-1+ and TIGIT+ Treg cells have distinct homing requirements to suppress autoimmune uveitis in mice.Mucosal immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The role of regulatory T cells (Treg cell) in controlling autoimmune disease is an area of intense study. As such, the characterization and understanding the function of Treg markers has the potential to provide a considerable impact in developing treatments and understanding the pathogenesis of autoimmune diseases. One such inhibitory Treg cell marker that has been recently discovered is T cell immunoglobulin and ITIM domain (TIGIT). In this review, we discuss what is known about the expression and function of TIGIT on Treg cells, and we discuss the relationship between TIGIT expressing Treg cells and different autoimmune diseases such as atopic dermatitis, autoimmune thyroiditis, type 1 diabetes, autoimmune uveitis, aplastic anemia, multiple sclerosis, systemic lupus erythematosus, arthritis, and colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.